References
- Jacobs S C. Spread of prostate cancer to bone. Urology 1983; 21: 337–44
- Kwak C, Seong J, Park M S, et al. Prognostic Significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168: 995–1000
- Lee C T, Oesterling J E. Using prostate-spe-cific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 1997; 24: 389–94
- Oken M M, Creech R H, Tormey D C, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55
- Demetri G D, Kris M, Wade J, et al. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412–25
- Gough I R, Furnival C M, Schilder L, et al. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983; 19: 1161–65
- McCormack H M, Horne D J, Sheather S, et al. Clinical applications of visual analog scales: A critical review. Psychol Med 1988; 18: 1007–19
- Wymenga L FA, Boomsma J HB, Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate specific antigen and alkaline phosphatase. BJU Int 2001; 88: 226–30
- Saad F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol 2002; 29(Suppl 21)19–27
- Smith M R, Eastham J, Gleason D M, et al. Randomised controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008–12
- Lee M V, Fong E M, Singer F R, et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602–8
- Terogen O, Heikkila P, Kontinen Y T, et al. MMP inhibition and down regulation by bisphosphonates. Ann NY Acad Sci 1999; 878: 453–65
- Keller E T. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today 2002; 38: 91–102
- Garnero P. Markers of bone turnover in prostate ancer. Cancer Treat Rev 2001; 27: 187–92